Quick Answer
Inmune Bio, Inc. reported Common Stock Shares Outstanding of 26.59 million shares for the year ending 2025.
- Inmune Bio, Inc. showed an increase of +19.3% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: 9.74 million shares | Q2 2019: 10.76 million shares | Q3 2019: 10.76 million shares | Q1 2020: 10.75 million shares | Q2 2020: 10.90 million shares | Q3 2020: 13.45 million shares | Q1 2021: 14.93 million shares | Q2 2021: 15.13 million shares | Q3 2021: 17.84 million shares | Q1 2022: 17.95 million shares | Q2 2022: 17.95 million shares | Q3 2022: 17.95 million shares | Q1 2023: 17.95 million shares | Q2 2023: 17.95 million shares | Q3 2023: 17.95 million shares | Q1 2024: 17.95 million shares | Q2 2024: 19.71 million shares | Q3 2024: 22.17 million shares | Q1 2025: 22.93 million shares | Q2 2025: 26.59 million shares | Q3 2025: 26.59 million shares.
- Over the full 9 years of available data (2017 to 2025), Inmune Bio, Inc.'s Common Stock Shares Outstanding has grown by 219.6%.
- Historical annual values: Fiscal year 2025: 26.59 million shares | Fiscal year 2024: 22.28 million shares | Fiscal year 2023: 17.95 million shares | Fiscal year 2022: 17.95 million shares | Fiscal year 2021: 17.84 million shares | Fiscal year 2020: 13.48 million shares | Fiscal year 2019: 10.77 million shares | Fiscal year 2018: 8.72 million shares | Fiscal year 2017: 8.32 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: